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Abstract
Primary hyperparathyroidism (PHPT) is a common disorder in which parathyroid hormone (PTH) 
is excessively secreted from one or more of the four parathyroid glands. A single benign 
parathyroid adenoma is the cause in most people. However, multiglandular disease is not rare and 
is typically seen in familial PHPT syndromes. The genetics of PHPT is usually monoclonal when a 
single gland is involved and polyclonal when multiglandular disease is present. The genes that 
have been implicated in PHPT include proto-oncogenes and tumour-suppressor genes. 
Hypercalcaemia is the biochemical hallmark of PHPT. Usually, the concentration of PTH is 
frankly increased but can remain within the normal range, which is abnormal in the setting of 
hypercalcaemia. Normocalcaemic PHPT, a variant in which the serum calcium level is persistently 
normal but PTH levels are increased in the absence of an obvious inciting stimulus, is now 
recognized. The clinical presentation of PHPT varies from asymptomatic disease (seen in 
countries where biochemical screening is routine) to classic symptomatic disease in which renal 
and/or skeletal complications are observed. Management guidelines have recently been revised to 
help the clinician to decide on the merits of a parathyroidectomy or a non-surgical course. This 
Primer covers these areas with particular attention to the epidemiology, clinical presentations, 
genetics, evaluation and guidelines for the management of PHPT.
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Primary hyperparathyroidism (PHPT) is a common disorder characterized by an excessive 
secretion of parathyroid hormone (PTH) from one or more of the four parathyroid glands. It 
is typically due to a single benign parathyroid adenoma. The classic disorder is associated 
with hypercalcaemia, but a normocalcaemic variant is now recognized. The incidence of 
PHPT increased markedly in countries where biochemical screening tests have come into 
use. With the increase in incidence of PHPT, its clinical presentation has changed from a 
symptomatic disease with skeletal (for example, fragility fractures) and renal (for example, 
kidney stones) manifestations to one in which patients are not overtly symptomatic. 
Asymptomatic PHPT has been the subject of four decades of discussion about how best to 
deal with a disorder that can be cured by surgery but which presents often as an incidental 
discovery without symptoms. It is important to note that individuals who are ‘asymptomatic’ 
can still show evidence of complications and target organ involvement. Conversely, 
symptomatic PHPT still occurs and can be the most prominent form of the disease in 
countries where biochemical screening tests are not routinely used. This Primer provides, 
within a historical framework, the evolution of this disease clinically, advances in our 
knowledge of its epidemiology, pathogenesis, presentations, evaluation and management.
Epidemiology
When the first several hundred individuals with PHPT were described in the 1930s at the 
Massachusetts General Hospital, 57% had kidney stones, 8% had peptic ulcer disease and 
23% had bone complications1. Over the past five decades, the clinical presentation of PHPT 
has changed in several regions of the world2. Since the 1970s, PHPT has become more 
routinely diagnosed at an asymptomatic stage owing to increased screening2. The clinical 
evolution of PHPT from symptomatic to asymptomatic has occurred primarily in the United 
States and Europe, although other countries have more recently appreciated this change as 
well3. One of the vexing issues that clinicians deal with is whether the asymptomatic patient 
has evidence of target organ involvement. This is the reason why this group of patients has 
been the subject of such intense interest over the past four decades.
Comparing prevalence and clinical aspects of the disease within and between countries is 
problematical owing to varying levels of screening availability and sources of information 
(for example, referral centres versus country demographics). Nevertheless, summarizing the 
varying presentations of PHPT globally is instructive.
North America
PHPT presents primarily as an asymptomatic disorder in North America4. The prevalence of 
kidney stones and skeletal manifestations has markedly decreased in the past 40 years. In 
addition, prevalence data show considerable sex and ethnic differences. The Kaiser 
Permanente Health Care database in California, USA, showed a significantly higher 
incidence of PHPT among black individuals (92 per 100,000 in women and 46 per 100,000 
in men) than in white individuals (81 per 100,000 in women and 29 per 100,000 in men)5. 
Other races demonstrated a lower incidence. In Asian-American populations, for example, 
the incidence was 52 per 100,000 in women and 28 per 100,000 in men. In the Hispanic 
population, the incidence was 49 per 100,000 in women and 17 per 100,000 in men5. During 
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the 15-year period of this study, the Kaiser Permanente Health Care database showed an 
overall threefold increase in incidence, which is perhaps a reflection of increased screening5 
(FIG. 1). Another survey conducted in the United States estimated a PHPT prevalence of 
0.86% for the general population6. The prevalence of normocalcaemic and hypercalcaemic 
PHPT in Canada was evaluated in the Canadian Multicenter Osteoporosis Study7 and was 
found to be 3.3% and 1.4%, respectively.
In the United States, a 60% increase in the incidence of parathyroid cancer, a very rare 
presentation of PHPT, was reported between 1988 and 2003 (REF. 8). This apparent increase 
could be owing to greater awareness of the entity and uncertainty, at times, in the 
pathological characteristics of parathyroid cancer versus parathyroid adenoma and the 
tendency, over the years, to favour a cancer diagnosis when uncertain.
Europe
In Europe, PHPT is also identified most commonly as a relatively common, asymptomatic 
disorder. A Swedish study identified PHPT in 1.6% of women and 0.3% of men9. The 
incidence of PHPT also increased in Denmark between 1999 and 2010 (REF. 10), probably 
reflecting increased screening. Monitoring in Scotland, UK, over a 20-year period (1997–
2006) showed, as has been shown everywhere, that PHPT predominantly affects women11.
Latin America
In Latin America, 47% of patients presented with asymptomatic disease in a case series of 
124 patients, whereas 25% had overt skeletal manifestations12. Approximately 44% of 
people with PHPT had kidney stones at the time of presentation in a study from Argentina13. 
In Brazil, 81.8% of patients were asymptomatic at the time of presentation14. However, 
kidney stones and osteitis fibrosa cystica (a distinct PHPT-associated complication that is 
associated with bone loss, excessive fibrosis of the collagen matrix and the formation of 
bone cysts) were present in 18.2% and 6.1% of patients, respectively. The mean age was 
61.1 years (±16 years).
Asia
Although epidemiological studies on the prevalence of PHPT have not been conducted in 
Asian countries, it seems that, in countries such as China and India, patients with PHPT still 
present with classic PHPT, namely, with organ manifestations and relatively high serum 
levels of calcium15,16. However, a clear trend for PHPT to present more commonly as an 
asymptomatic disorder in China has been emerging over the past 5–10 years17. In the 35-
year period between 1958 and 1993, 97% of PHPT in China was characterized by kidney 
stones, classic skeletal lesions (for example, osteitis fibrosa cystica, generalized skeletal 
demineralization and pathological fractures) and other features of symptomatic PHPT16. 
Recently, the clinical profile of 249 patients with PHPT who were diagnosed and treated 
from 2000 to 2010 in one clinical centre in China was compared to American patients17,18. 
Chinese patients were younger (51.3 years of age) than American patients (66.4 years of 
age) at diagnosis and were less likely to be women (female/male ratio of 2.07/1) than 
patients in New York City, USA (female/male ratio of 4.5/1). The average calcium levels 
(11.7 ± 1.4 mg per dl in China versus 10.6 ± 0.6 mg per dl in the United States), PTH levels 
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(402 pg per ml (range: 103–2,700 pg per ml) in China versus 68 pg per ml (range: 48–95 pg 
per ml) for the United States) and creatinine levels (1.03 mg per dl (range: 0.55–2.75 mg per 
dl) for China and 0.79 mg per dl (range: 0.59–1.23 mg per dl) for the United States) in 
serum were all significantly higher, whereas the average 25-hydroxyvitamin D concentration 
(13 ng per ml (range: 5–30 ng per ml) in China versus 37 ± 16 ng per ml in the United 
States) was much lower. Among all Chinese patients, 60% manifested classic symptoms 
related to PHPT, including polydipsia and polyuria (79.7%), kidney stones (78.4%), bone 
pain (69.9%) and fatigue (62.8%).
However, the clinical profile of Chinese patients is changing. The proportion of 
asymptomatic patients with PHPT rose from <20% before 2006 to ~50% in the period 
2007–2010. This change has largely been driven by the availability of routine serum calcium 
testing and the incidental discovery of a parathyroid gland on neck ultrasonography17. A 
survey in Hong Kong, China, also demonstrated a steady increase in the prevalence of 
asymptomatic PHPT from 5% between 1973 and 1982 to 39% between 1983 and 1992 and 
to 59% between 1993 and 2002 (REF. 19).
Although China seems to be witnessing a change in the clinical presentation of PHPT, other 
Asian countries including India, Iran, Pakistan, Saudi Arabia and Thailand still mostly report 
symptomatic PHPT; asymptomatic PHPT remains rare in these regions (0–2.2% of all PHPT 
diagnoses)15,20–24. The number of patients diagnosed in a single centre in north India 
steadily increased between 1990 and 2010, with 28 cases diagnosed during 1990–1999 and 
174 cases during 2000–2010. PHPT was predominantly diagnosed in women (70.3%), and 
virtually all 202 patients (99.1%) were symptomatic with kidney and skeletal involvement25. 
A similar presentation was described in Western India20.
Parathyroid carcinoma has been reported in 6% of patients with PHPT in China (a total of 
235 patients) and was even as high as 11.5% (a total of 87 patients) in Japan17,26. These 
figures are much higher than in countries in the west. However, a decreasing trend for the 
incidence of parathyroid carcinoma over the past 10 years was noted in Chinese patients 
with PTHT17.
Africa and Australia
Information about PHPT in Africa is limited. A retrospective analysis of 28 patients with 
PHPT in a referral hospital in Durban, South Africa, between 2003 and 2009 reported that 
PHPT was still presenting with symptoms27.
In a recent study from Australia, 561 patients with PHPT were followed up for >30 years. 
Mortality figures were higher than the general Australian population28.
Summary
In summary, the breakdown of individuals with symptomatic versus asymptomatic PHPT 
has regional specificity. In countries for which screening biochemistries are not routinely 
part of the health care system, symptomatic PHPT seems to predominate. In countries where 
screening biochemistries are routine, asymptomatic PHPT takes centre stage. In short, 
symptomatic disease tends to be more common in countries where the prevalence is lower. 
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All studies, independent of the breakdown of symptomatic versus asymptomatic PHPT in a 
given country, have shown that postmenopausal women are affected much more commonly 
than men. The incidence rates between premenopausal women and men are simi-lar5. 
European studies suggest increased mortality29, but mortality rates are not higher in North 
America30.
Mechanisms/pathophysiology
The pathophysiology of PHPT relates to the loss of the homeostatic control of PTH 
synthesis and secretion (FIG. 2), leading to increased PTH secretion by individual cells or 
increased parathyroid cell proliferation, but with each cell secreting a normal level of PTH.
In parathyroid hyperplasia, the increased number of parathyroid cells maintain their normal 
sensitivity to calcium, whereas in parathyroid adenomas, the parathyroid cells show a lower 
than normal sensitivity to the inhibitory action of calcium (REFS 31,32). Both conditions give 
rise to PHPT and can cause hypercalcaemia.
PTH endocrine axis and target tissues
Calcium is the main regulator of PTH secretion, with an inverse sigmoidal relationship 
between calcium concentration and PTH release that is mediated by the interaction of 
calcium with the calcium-sensing receptor (CASR) present on the surface of parathyroid 
cells33 (FIG. 3). The active form of vitamin D — 1,25(OH)2D — suppresses PTH 
transcription and parathyroid cell proliferation. These effects are not only due to circulating 
1,25(OH)2D synthesized in the kidney but also due to local synthesis by the 1α-25-
hydroxyvitamin D hydroxylase enzyme present in parathyroid cells34. An increase in the 
serum levels of phosphate indirectly stimulates PTH synthesis and secretion as well as 
parathyroid cell proliferation by binding to calcium, thereby lowering the serum calcium 
concentration35. Some studies have suggested that serum phosphate can directly affect 
parathyroid cell function by increasing PTH mRNA stability36. Finally, studies in rats and 
rat parathyroid cell cultures have shown that fibroblast growth factor 23 (FGF23), released 
from osteocytes (bone cells involved in mechanosensing and mineral homeostasis), inhibits 
PTH synthesis and secretion and, perhaps, parathyroid cell proliferation by binding to its 
cognate FGF receptor 1 (FGFR1) and the coreceptor Klotho on the membrane of parathyroid 
cells37. The relevance of this observation to the pathogenesis of PHPT in humans remains 
uncertain. Indeed, patients with PHPT have increased levels of FGF23 in association with 
high serum levels of PTH, suggesting that the increased FGF23 levels might be an adaptive 
response to counteract increased 1,25(OH)2D levels as a consequence of high PTH levels38.
The main target organs of PTH are the bone and the kidney. PTH is a central regulator of 
bone homeostasis, through its action on bone-forming osteoblasts, osteocytes and bone-
resorbing osteoclasts39. The final effect of PTH on bone mass is either anabolic or catabolic 
and will depend on the dose and periodicity of PTH signalling40. In healthy individuals, 
PTH is released both with circadian dynamics and in a pulsatile manner, such that its dual 
anabolic and catabolic actions are well balanced. Conversely, in patients with PHPT, the 
chronically increased PTH levels lead to bone loss mediated by the receptor activator of 
nuclear factor-кβ ligand (RANKL, also known as TNFSF11), osteoporosis (particularly at 
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sites that are more rich in cortical bone) and fragility fractures. It is not clear to what extent 
changes in these secretory dynamics are associated with bone loss and fragility fractures in 
PHPT41.
In the kidney, PTH stimulates tubular calcium reabsorption and phosphate excretion and 
stimulates the activity of 1α-25-hydroxyvitamin D hydroxylase. When patients with PHPT 
develop hypercalciuria, the filtered calcium load is greater than the capacity of the kidney to 
reabsorb calcium efficiently, even under the influence of PTH42.
Aetiological factors of tumorigenesis
PHPT is usually (>90%) sporadic and caused by a solitary benign adenoma (85–90%), less 
frequently by multiglandular involvement consisting of either multiple adenomas or 
hyperplasia of all four glands (5–10%), and very rarely by parathyroid carcinoma (<1%)43. 
Multiglandular involvement may present in an asynchronous manner and, therefore, can be 
confused with single-gland adenoma when only one abnormal gland is found at the time of 
initial surgery44. Over time, another parathyroid adenoma can become clinically evident. 
Conversely, multiple adenomas, presenting simultaneously, can also occur45. Very rarely, 
PHPT may be caused by ectopic secretion of PTH by a non-parathyroid tumour44.
The aetiology of PHPT remains elusive in the majority of patients. A history of external 
neck irradiation in childhood46, exposure to a nuclear incident in adults47 and long-term 
lithium therapy (as opposed to short-term lithium therapy that may cause secondary 
hyperparathyroidism)48 are present in a few cases. PHPT may also be part of hereditary 
endocrine syndromes, including multiple endocrine neoplasia type 1 (MEN1) and MEN2A, 
MEN4 (which is a MENl-like condition (associated with one or more of the main MEN1-
associated tumours, but without MEN1 gene mutations), hereditary hyperparathyroidism-
jaw tumour syndrome, familial isolated hyperparathyroidism, familial hypocalciuric 
hypercalcaemia (FHH) and neonatal severe hyperparathyroidism (TABLE 1). The 
identification of hereditary cases can sometimes be difficult in the absence of a family 
history and, in these settings, a de novo germline mutation should be considered.
Molecular mechanisms of tumorigenesis
Evaluation of the clonal status of a parathyroid tumour (including adenomas and 
carcinomas), has shown that most are monoclonal, which implies that the tumours derive 
from a single abnormal cell49,50. By contrast, hyperplastic parathyroid glands probably 
originate from a stimulus for generalized (polyclonal) parathyroid cell proliferation, even 
though monoclonal tumours may also occur in this context51. Thus, in some cases, 
apparently hyperplastic glands are in fact adenomas. The clonality of parathyroid tumours 
has also been shown in MEN1 (REFS 52,53).
The clonality ofmost parathyroid tumours suggests the involvement of genes that control 
parathyroid cell growth and/or PTH synthesis or secretion. Two broad categories of genes 
might be involved: proto-oncogenes and tumour-suppressor genes (FIG. 4). Notably, 
tumorigenesis is often a multistep process during which cells acquire a series of mutations or 
deletions in multiple genes, which can in some instances coexist. Moreover, epigenetic 
changes could contribute, in certain specific ways, to tumour development. Several genes 
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have been implicated in sporadic and hereditary forms of PHPT. Although syndromic forms 
account for <10% of PHPT, the identification of genes involved in the pathogenesis of 
inherited forms has contributed to the understanding of parathyroid tumorigenesis.
FIGURE 5 summarizes the main molecular mechanisms involved in parathyroid 
tumorigenesis.
Syndromic forms of PHPT
Multiple endocrine neoplasia type 1—MEN1 shows an autosomal dominant pattern of 
inheritance, and the genetic basis responsible for the predisposition to tumour development 
is a germline mutation in MEN1 (encoding menin) (REF. 54) (FIG. 5; TABLE 1). More than 
1,000 mutations have been identified in ~80% of probands and families with MEN1. The 
mutations are distributed across the translated region of the gene without hotspots; the 
majority of mutations predict truncation or the absence of the encoded protein (menin)55. 
Individuals with MEN1 typically inherit the inactivating germline mutation from an affected 
parent, but up to 10% of affected individuals have a de novo germline mutation. An acquired 
somatic inactivation of the other copy of MEN1 in one parathyroid cell, leading to the 
absence of functional menin, contributes to the clonal origin of the parathyroid tumour and 
other tumours in the patient54 (FIG. 5).
Menin is a 610 amino acid protein that interacts in vitro with various proteins, including the 
transcription factor AP-1 (encoded by JUN), nuclear factor-кB and the SMAD transcription 
factors, as well as other cell cycle regulators and cytoskeletal proteins, all suggesting a role 
in multiple biological pathways56. The interaction of menin with a histone methyltransferase 
complex, including the histone-lysine N-methyltransferases MLL1 (encoded by KMT2A) 
and MLL2 (encoded by KMT2D), can be involved in MEN1-associated tissue-selective 
tumorigenesis57, mediated by the transcriptional activation of CDKN1B (encoding cyclin-
dependent kinase inhibitor 1B) and CDKN2C58,59. Recently, a germline mutation of the aryl 
hydrocarbon receptor-interacting protein gene (AIP) has been reported in a patient with 
sporadic MEN1 syndrome60. Mutations of other genes, encoding cyclin-dependent kinase 
inhibitors, including CDKN1A, CDKN1B (MEN4, see below), CDKN2B and CDKN2C, 
have been identified in MEN1 mutation-negative kindreds with MEN1 disease61.
Multiple endocrine neoplasia type 2A—The inheritance of MEN2A is autosomal 
dominant and due to gain-of-function mutations in the RET proto-oncogene (TABLE 1). 
RET is a tyrosine kinase receptor that is involved in the control of growth and differentiation 
in developing tissues, including those derived from the neural crest. A RET mutation at 
codon 634 is highly associated with the development of PHPT62. Parathyroid tumours occur 
in 10–25% of patients with MEN2A; in ~50% of patients that develop tumours, no 
hypercalcaemia is observed62.
Multiple endocrine neoplasia type 4—In 2006, Pellegata et al.63 described a rat model 
that spontaneously developed multiple neuroendocrine tumours, with a spectrum similar to 
that of MEN1 and MEN2 syndromes. The same authors showed that a homozygous 
germline mutation in Cdkn1b, encoding p27, was responsible for this condition, which was 
named MENX63. Heterozygous germline mutations of the human homologue CDKN1B 
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were identified in kindreds with classic MENl-associated tumours (for example, pituitary, 
parathyroid and pancreatic tumours) occurring in association with uncommon MENl-
associated or non-associated tumours (for example, adrenal and thyroid tumours, and 
gonadal and renal tumours, respectively) without a mutation in MEN1 (REF. 64). These 
kindreds with MENl-associated tumours and CDKN1B mutations are now designated as a 
new syndrome called MEN4 (REFS 65,66) (TABLE 1). In Gl phase cells (resting), p27 
(KIP1) is found in the nucleus, where it controls cell cycle progression from G1 to S phase, 
the mechanism for which involves inhibiting the cyclin E-CDK2 and cyclin A–CDK2 
complexes. In proliferating cells, p27 (KIP1) is also localized to the cytoplasm, where it 
seems to have a pro-oncogenic function67.
Hereditary hyperparathyroidism-jaw tumour syndrome—Mutations in CDC73 are 
responsible for hereditary hyperparathyroidism-jaw tumour syndrome68,69 (TABLE 1). This 
is a rare autosomal disorder consisting of parathyroid tumours, with a high prevalence of 
parathyroid carcinomas (l5%), ossifying fibromas of the mandible and maxilla and, 
occasionally, renal and uterine lesions. CDC73 is a tumour-suppressor gene that encodes 
parafibromin, a 53l amino acid nuclear protein that is also expressed in the kidney, heart, 
adrenal glands and skeletal muscle. Parafibromin is a member of the human polymerase-
associated factor 1 (PAF1) complex, which regulates transcription and chromatin 
modification70 (FIG. 5).
Non-syndromic forms of hyperparathyroidism Familial isolated 
hyperparathyroidism—Familial isolated hyperparathyroidism is a familial form of PHPT 
in which no other manifestations typical of a syndromic form of PHPT are present, 
suggesting incomplete penetrance. The disorder is genetically heterogeneous, but mutations 
of MEN1, CDC73, CASR and CDKN1B have been reported in a minority of cases71,72.
FHH and neonatal severe hyperparathyroidism—FHH and neonatal severe 
hyperparathyroidism are due to inactivating mutations in CASR. FHH is genetically 
heterogeneous and three different variants have been identified73. Most cases of FHH are 
caused by heterozygous inactivating mutations of CASR on 3q13.3–q21.1 (FHH type 1)74. 
The mutations are distributed along the entire gene, but are most predominant in the regions 
encoding the extracellular and transmembrane domains33. Approximately 30% of patients 
with FHH type 1 lack mutations in CASR. Recent studies have identified two additional 
forms of FHH linked to chromosome 19, which are due to mutations of G protein subunit all 
(GNA11; FHH type 2)75 and adaptor-related protein complex 2σ 1 subunit (AP2S1; FFH 
type 3)75. Neonatal severe hyperparathyroidism results from inheritance of two abnormal 
CASR alleles in either the homozygous or the compound heterozygous state73.
The main sites where the CASR is mainly expressed are parathyroid cells and those in the 
thick ascending loop of the renal tubule. Reduction or loss of function of CASR results in 
impaired calcium inhibition of PTH secretion in parathyroid cells and in reduced calcium 
excretion at any serum calcium concentration in the kidney33. Gene inactivation studies in 
mice support the pathogenetic role of CASR inactivation in FHH type 1 and neonatal severe 
hyperparathyroidism76.
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Sporadic form of PHPT
Parathyroid adenoma—Overexpression of cyclin D1 (encoded by CCND1) and 
mutations of MEN1 are well-known factors in the pathogenesis of sporadic parathyroid 
adenomas44. CCND1 was discovered in parathyroid adenomas and mapped on 11q13. In 
these tumours, a pericentromeric inversion causes a tumour-specific DNA rearrangement of 
CCND1 with PTH and is responsible for transcriptional activation and overexpression of 
cyclin D1 (REFS 77,78) (FIG. 5). This genetic abnormality has been detected in ~8% of 
sporadic parathyroid adenomas, although an increased expression of CCND1 has been 
reported in ~20–40% of cases. Cyclin D1 plays an important part in the regulation of cell 
cycle progression. Its effects on proliferation are mediated by the phosphorylation of 
retinoblastoma protein (RB). Biallelic-acquired inactivating MEN1 mutations have been 
described in 12–35% of sporadic parathyroid adenomas79–81.
Other genetic abnormalities have been detected in a small proportion of parathyroid 
adenomas, including mutations in CDC73 (REFS 82,83), CDKN1B84 and AIP85. 
Interestingly, mutations were germline in two patients with CDKN1B mutations and in one 
carrying a mutation in AIP Contradictory results have been reported on the presence of 
CTNNB1 (encoding β-catenin) mutations involving serine/threonine phosphorylation86,87. 
Up to 30 proteins, involved in various cellular pathways (for example, response to biotic 
stimuli, cell organization and signal transduction), are differentially expressed in normal 
parathyroid and parathyroid adenomas88. Of these various proteins, 14-3-3ζ/δ may be one of 
the key proteins in the pathogenesis of parathyroid adenoma.
Parathyroid carcinoma—Loss of RB1 expression in parathyroid carcinoma was initially 
reported by Cryns et al.89 and was proposed as a diagnostic tool, but contradictory results 
were shown by others90 and no abnormalities in the coding or promoter regions of RB1 have 
been identified91. CDC73 is the most common mutated gene (up to 70%) in sporadic 
parathyroid carcinoma69,90,91. Interestingly, mutations are germline in about one-third of 
patients, suggesting that they may be affected by hereditary hyperparathyroidism-jaw 
tumour syndrome or a variant instead of sporadic tumours90,91. Another mechanism of 
CDC73 inactivation — methylation of the promoter — has been reported in a small subset 
of parathyroid carcinoma92. Recently, using whole-exome sequencing, germline and somatic 
mutations have been detected in 4 out of 22 (18%) patients with parathyroid carcinoma. 
Occasional mutations of MEN1 have also been reported93. Two recent studies suggest a 
potential role of microRNA-296 as a novel oncosuppressor gene in parathyroid 
carcinoma94,95.
Diagnosis, screening and prevention
Clinical manifestations
Osteitis fibrosa cystica describes the skeletal manifestations of PHPT when the disease is 
advanced. It is typically characterized by bone pain, skeletal deformities and pathological 
fractures12 (FIG. 6). Conversely, in asymptomatic PHPT, skeletal involvement is typically 
seen only by bone mineral density (BMD) testing, which shows a reduction, especially of 
the cortical bone compartment best seen at the distal one-third of the radius site. Recent data 
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using high-resolution peripheral quantitative CT (HRpQCT) have demonstrated that both 
cortical and trabecular bone compartments are affected in PHPT96,97. Involvement of the 
trabecular compartment is further documented by the trabecular bone score, which is also 
reduced in the lumbar spine98,99, and by fractures that are increased at both vertebral and 
non-vertebral sites100,101. These observations support recommendations to include vertebral 
imaging either by radiography, CT or vertebral fracture assessment to evaluate skeletal 
manifestations of PHPT (BOX 1). After parathyroidectomy, BMD increases even in patients 
with mild disease. When PHPT is associated with osteitis fibrosa cystica, the improvement 
in BMD can be so marked as to increase into the normal range42,102.
The prevalence of kidney stones in PHPT has varied over the years and, to a certain extent, 
is dependent on the use of imaging modalities to detect them. Overt kidney stone disease 
(symptomatic kidney stones) has declined from 60% when series of PHPT were first 
reported about 50 years ago to more-current estimates of ~20%103–105. By contrast, 
abdominal imaging of asymptomatic patients with PHPT is yielding a higher prevalence of 
silent stones and nephrocalcinosis than was thought to be the case in asymptomatic 
PHPT106,107.
Weakness and fatigue were initially thought to be associated with a neuromuscular 
syndrome, characterized by atrophy of type II muscle fibres of the proximal musculature108. 
However, over time, as the disease has evolved into a more asymptomatic phenotype, these 
objective findings on neurological examination are no longer seen109. Among asymptomatic 
patients with PHPT, a detailed examination using electroneurography is required to disclose 
subtle abnomalities of peripheral nerves110. General symptoms — in particular, fatigue, 
weakness, anxiety and mood alterations — along with impairment in quality of life (QOL) 
may or may not improve after surgical cure (see below)111.
Peptic ulcer disease, which used to be considered a frequent complication of PHPT, is now 
rarely seen and is almost exclusively detected in patients with MEN1 or MEN4 syndromes, 
who can develop gastrin-producing tumours112. Similarly, the association between PHPT 
and acute pancreatitis, apart from that related to hypercalcaemia per se, remains to be 
established113.
With regard to cardiovascular health, hypertension, premature atherosclerosis, valve 
calcification, left ventricular hypertrophy and arrhythmias have been reported in patients 
with PHPT114–116, but the data on outcome as well as the mechanisms involved are 
inconclusive. The Nurses’ Health study114 showed an increased incidence of PHPT in 
women with hypertension compared with those with normal blood pressure values. In 
addition, no evidence of increased left ventricular mass or diastolic dysfunction in patients 
with biochemically mild PHPT was found, but the finding of higher serum calcium and PTH 
levels in patients with diastolic dysfunction suggests that disease severity of PHPT may be 
associated with cardiac manifestations115. Iwata et al.116 observed that mild PHPT was 
associated with subclinical aortic valve calcification. Serum PTH levels, but not serum 
calcium levels, were a more important predictor of aortic valve calcification than traditional 
cardiovascular risk factors.
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Laboratory diagnosis
Confirmed hypercalcaemia is a major indicator of PHPT117 (BOX 1). Either total calcium 
(albumin corrected) or ionized calcium can be measured. As ~45% of total serum calcium is 
bound to albumin, calculating the corrected calcium level involves adjusting the level of total 
serum calcium by the level of serum albumin. The many technical issues related to the direct 
measurement of ionized calcium lead many experts to recommend the adjusted total calcium 
as the best way to report the serum calcium concentration. It is helpful to repeat the serum 
calcium measurements several times over the course of a 3–6–month period and to retrieve 
historical serum calcium values that are available from the patient’s record.
A major diagnostic linchpin in PHPT is the measurement of circulating PTH. Second-
generation assays that measure the so-called intact PTH molecule [PTH(1–84)] show 
crossreactivity with the large, inactive, amino-truncated fragment [PTH(7–84)]. This 
fragment can also be detected in individuals without PHPT and can accumulate in patients 
with renal failure. The third-generation or bio-intact assay uses a labelled antibody that 
recognizes an extreme N-terminal PTH fragment [PTH(1–4)], preventing crossreactivity 
with PTH(7–84). However, this assay also detects a post-translational form of PTH in the 
region 5–20 that is not truncated. This post-translationally modified form of PTH (N-PTH) 
represents 10% of PTH in healthy individuals and 15% in patients with chronic kidney 
disease, and is not thought to be active. In parathyroid cancer, it seems to be 
overrepresented118. There are few studies comparing the diagnostic sensitivity between the 
second-generation and third-generation assays, but both perform generally well119.
In PHPT, the serum PTH levels may be frankly increased or in the normal range. However, a 
‘normal’ PTH value in someone with hypercalcaemia is clearly not a normal physiological 
value. For example, in a large epidemiological study in Scotland, UK11, patients with 
hypercalcaemia on two or more occasions and an intact serum PTH concentration of >28 pg 
per ml (reference range: 19–65 pg per ml) were considered to have PHPT. Indeed, in 
individuals without PHPT who become hyper-calcaemic, PTH should be completely 
suppressed and undetectable by immunoassay.
Normocalcaemic PHPT
Normocalcaemic PHPT has been increasingly detected in patients who are evaluated for low 
BMD117. Other causes of hyperparathyroidism due to a normal physiological stimulus to 
increased PTH levels — secondary hyperparathyroidism states — should be excluded (BOX 
2). Bone resorption inhibitors, such as bisphosphonates and denosumab, usually cause 
increases in serum PTH concentrations, rendering a diagnosis of normocalcaemic PHPT 
under these conditions uncertain120,121. The diagnosis of parathyroid gland autonomy in the 
setting of chronic kidney disease is more challenging. In patients with advanced chronic 
kidney disease, the presence of hypercalcaemia along with a progressive rise in serum PTH 
levels is usually referred to as tertiary hyperparathyroidism. In advanced-stage chronic 
kidney disease, intact PTH levels in serum should be maintained between 150 and 550 pg 
per ml to avoid low-turnover or high-turnover bone disease122.
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Evaluation of patients with PHPT
Laboratory evaluation should include measurements of serum phosphate, renal function tests 
and measurements of serum 25-hydroxyvitamin D (BOX 1). The 24-hour urinary calcium 
level should also be measured and, if >400 mg per day, a complete stone risk profile analysis 
should also be measured. A urinary calcium clearance/creatinine clearance ratio of <0.01 
suggests, but does not prove, FHH; the age of the patient should also be taken into account 
as FHH exhibits virtually 100% penetrance by 30 years of age. In addition, in FHH, a family 
history of hypercalcaemia can often be obtained and should be followed by genetic 
screening.
Serum phosphate levels are usually low in severe PHPT and in the lower range of normal in 
milder forms of PHPT123. Bone turnover markers may be increased, the degree to which can 
be a function of the severity ofthe bone disease (BOX 1). Renal imaging by ultrasound, X-
ray or CT should be performed to detect the presence of kidney stones or nephrocalcinosis. 
Measurement of BMD by dual-energy X-ray absorptiometry should be obtained at the 
lumbar spine, the hip (total hip and femoral neck) and the distal one-third of the radius in all 
patients with PHPT. Depending on availability, additional tests such as the trabecular bone 
score or HRpQCT may be helpful121. In young patients with PHPT (<30 years of age), those 
with multiglandular disease, a family history of PHPT (affected first-degree relatives) or in 
those with parathyroid cancer, specific genetic testing (TABLE 1) may be necessary117.
Management
Resection of a parathyroid adenoma (parathyroidectomy) in patients with PHPT is usually 
curative124,125. Following successful parathyroidectomy, biochemical abnormalities resolve 
and BMD improves126 with a decreased risk of bone fracture127 and kidney stones128. There 
may also be improvements in neurocognition and QOL, although randomized controlled 
trials (RCTs) have failed to show consistent effects129–131. Similarly, cardiovascular end 
points have not been consistently reached, which might be related to subtle preoperative 
cardiovascular abnormalities of which the physiological importance is not yet understood. 
Furthermore, shortterm outcome measures raise questions about long-term improvement and 
whether the initial abnormalities were clearly related to the disorder132. Patients with 
symptomatic disease should be referred for parathyroidectomy if there are no medical 
contraindications. Medical therapy is an option for patients who meet surgical criteria but 
who cannot undergo surgery. The Conference Proceedings of the Fourth International 
Workshop on the Management of Asymptomatic Primary Hyperparathyroidism121 provide 
guidance about which patients with asymptomatic disease should be referred for surgery or 
those who can be managed expectantly.
Surgical management
A focused approach to remove the single parathyroid adenoma is now the procedure of 
choice at experienced surgical centres, with use of rapid intraoperative PTH 
measurements133. This procedure is preceded by successful localization of the parathyroid 
adenoma. Minimally invasive parathyroidectomy is not generally recommended unless the 
adenoma is identified by an imaging modality preoperatively. An example of a successful 
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preoperative localization of a parathyroid adenoma is shown in FIG. 7. The minimally 
invasive parathyroidectomy can be performed under local or regional anaesthesia with same-
day discharge. Surgical cure rates with minimally invasive techniques in experienced 
surgical centres exceed 98% with relatively low risk of surgical complications124,125.
Surgery should be considered for any patient who presents with evidence of symptomatic 
disease, including kidney stones within 10 years of diagnosis or the presence of a fragility 
fracture. Surgery is also acceptable for asymptomatic patients, provided they do not have 
medical contraindications121,133. The most recent revision of guidelines in 2014 (REF. 121) 
is generally consistent with the prior guidelines134 (BOX 3). The revised guidelines take into 
account the increased risk of vertebral fracture risk and subclinical kidney stones in 
asymptomatic individuals with PHPT100,101,107. Thus, the new guidelines recommend an 
evaluation for morphometric vertebral fractures and recommend further evaluation for 
nephrolithiasis or nephrocalcinosis, or increased risk of kidney stones (biochemical stone 
risk analysis).
The guidelines recommend genetic testing of patients suspected of having a genetic disorder, 
such as young patients (<30 years of age), patients with syndromic findings and/or a positive 
family history of syndromic PHPT, and patients with multiglandular disease, parathyroid 
carcinoma or atypical adenoma117,121. An atypical adenoma is defined histologically as 
containing features that are not typical of a benign adenoma. Some of these atypical features 
include an abundance of mitotic figures and cellular atypia. Sometimes, the atypical 
adenoma will present at the time of surgery as oddly adherent to surrounding structures. The 
surgical approach for patients with a genetic aetiology may differ from those with a sporadic 
parathyroid adenoma, in that multiglandular disease is more common when there is a genetic 
aetiology. Preoperative localization studies are recommended with ultrasound, 99m-
technetium-sestamibi nuclear scintigraphy, CT, MRI or PET scans. The choice of 
preoperative imaging depends on the experience of the surgical centre133.
Non-surgical management
Natural history and monitoring—Patients who do not meet surgical criteria or those 
who decline surgery should be monitored for signs of disease progression. The longest 
natural history study prospectively observed patients with primary hyperparathyroidism for 
15 years126. Biochemical parameters remained stable for 12 years, with a trend towards 
increasing levels of serum calcium in years 13–15. BMD remained stable for the first 8–10 
years of observation, with subsequent decline in densitometric parameters at the distal radius 
and hip. Over the 15-year follow-up period, 37% of patients with asymptomatic PHPT 
ultimately developed one or more criteria for surgery.
The revised guidelines121 recommend annual measurements of serum calcium, serum 
creatinine and estimated glomerular filtration rate. BMD should be monitored every 1–2 
years at the spine, hip and forearm. Follow-up vertebral imaging with X-ray or vertebral 
fracture analysis should be performed if clinically indicated for a patient with prospective 
height loss or new back pain. Imaging for new kidney stones should be performed if clinical 
suspicions emerge. Patients who do not meet criteria for parathyroidectomy on initial 
evaluation should be considered for surgical management if during the monitoring period 
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serum calcium concentrations rise to >1 mg per d1 above the upper normal limit, creatinine 
clearance falls to <60 cc per minute, the T-score at the spine, hip or distal one-third of the 
radius site falls below −2.5 or there is a substantial reduction in BMD, or if a vertebral 
fracture or kidney stone develops121.
Medical management—Adequate hydration and avoidance of dehydration is always 
recommended. Calcium intake should not be restricted and should follow national 
guidelines135. 25-hydroxyvitamin D levels of >20 ng per ml are recommended, although 
some experts continue to recommend levels of >30 ng per ml. To replete vitamin D when 
needed, initial doses of 600–1,000 IU daily are recommended, although a recent study 
showed that doses of 2,800 IU daily were well tolerated136. Serum calcium levels should be 
monitored during vitamin D supplementation.
Cinacalcet, a calcimimetic, is approved for specific indications in PHPT by the European 
Medicines Agency (EMA) and the US FDA. The EMA approved the use of cinacalcet for 
patients with hypercalcaemia who meet surgical criteria but in whom parathyroidectomy is 
not possible or not clinically ‘appropriate’ (REF. 137). Concurrent medical contraindications 
to surgery would be an example. Another example is a patient with PHPT who has had 
several negative operations in search for the elusive adenoma. The FDA approval is for 
severe hypercalcaemia in patients with PHPT who are unable to undergo 
parathyroidectomy138. Adverse effects of cinacalcet include nausea, vomiting, diarrhoea and 
headache, but are uncommon when the single 30 mg daily dose is used. Approval of 
cinacalcet followed the pivotal randomized, double-blind, placebo-controlled trial in 
PHPT139. The primary end point — normalization of serum calcium levels — was achieved 
in 73% of enrolled patients. Serum calcium levels remained in the normal range during the 
4.5-year open-label extension140. Subsequent prospective trials have shown similar 
results141–143. No significant effects on BMD have been observed with cinacalcet therapy.
Alendronate, a bisphosphonate, improved BMD in patients with PHPT144,145. In a 2-year 
randomized crossover study of alendronate versus placebo in postmenopausal women, the 
alendronate group had a significant increase in lumbar spine BMD at 2 years compared with 
baseline and compared with the control group144. The total hip BMD increased at 1 year and 
subsequently remained stable. Serum and urine concentrations of calcium and PTH did not 
change. A trial in men showed similar results145. Limited data suggest that oestrogen may 
also reduce bone resorption in PHPT, with no change in calcium or PTH levels146. In 
patients who require both a reduction in serum calcium levels and an improvement in BMD, 
combination therapy with cina-calcet and alendronate is reasonable, but has only been 
studied in a retrospective manner142,147,148.
Normocalcaemic PHPT—The optimal management strategy for the normocalcaemic 
variant of PHPT has not been established, but the 2014 guidelines offer 
recommendations121. Patients should be referred for parathyroidectomy if they have or 
develop complications of PHPT, even if they remain normocalcaemic. Serum calcium, PTH 
and creatinine levels should be monitored annually and BMD should be evaluated every 1–2 
years. Patients who develop hypercalcaemia can be managed as per the guidelines for 
asymptomatic PHPT. In one study, BMD improved following parathyroidectomy149 in 
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patients with hypercalcaemic PHPT126,150. There are little data available about the impact of 
medical therapy on patients with normocalcaemic disease. Alendronate improved BMD in a 
small cohort151.
Quality of life
Although we define asymptomatic PHPT as a condition in which classic target organs are 
not affected, many such patients report nonspecific symptoms, including fatigue, irritability, 
weakness, malaise, somatization, lack of mental clarity, sleep disturbance, anxiety and 
depression. These non-classic features of PHPT have been vexing and inconclusive to date 
as far as their association with PHPT and their reversibility after successful 
parathyroidectomy are concerned. However, these relatively common complaints among 
many patients with PHPT recall the classic descriptions of the disease of “mental fuzziness” 
that resolved with parathyroidectomy1.
Various cross-sectional and prospective studies have shown conflicting results with regard to 
the nonclassic symptoms of PHPT and improvement following parathyroidectomy152–162. 
The inconsistency of the data among these studies did not permit the expert Workshop Panel 
of the Fourth International Workshop on the Management of Asymptomatic Primary 
Hyperparathyroidism to recommend parathyroid surgery if such symptomatology was 
present in the absence of any clear surgical guidelines121,134.
Walker and colleagues163 published one of the most detailed neuropsychiatric evaluations in 
individuals with PHPT (TABLE 2). Thirty-nine postmenopausal women with mild, 
asymptomatic disease were prospectively studied before and after parathyroidectomy 
compared to 89 healthy age-matched controls. A battery of validated instruments to measure 
cognition and their relationships to underlying psychological symptoms and biochemical 
disease severity were used. At baseline, individuals with PHPT had worse symptom scores 
for depression and anxiety and worse performance on tests of verbal memory and non-verbal 
abstraction than controls. Six months following parathyroidectomy, these variables improved 
and were no longer different than controls. Baseline differences in cognition and 
improvement following parathyroidectomy were not associated with psychological 
symptoms or serum calcium or PTH concentrations.
Various older, observational studies have demonstrated deficits in QOL and neuropsychiatric 
features in individuals with the mild form of PHPT, with conflicting data regarding 
symptomatic improvement following parathyroidectomy. Many of these studies are 
unfortunately limited by methodological flaws, including a failure to apply standardized 
evaluation tools, small sample sizes, lack of controls or an inappropriate control population, 
and inclusion of subjects with symptomatic disease. A major problem inherent to this 
research is the lack of adoption of a validated disease-specific tool to evaluate QOL. Most 
studies use the 36-Item Short-Form Health Survey (SF-36), one of the most widely used 
general measures of QOL composed of eight domains on physical and mental health. 
Pasieka and colleagues164 validated a disease-specific QOL questionnaire, and Webb and 
colleagues165 state that validation studies are in progress for their disease-specific 
questionnaire.
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The most rigorous data available are from RCTs of parathyroidectomy versus 
observation129–131. Rao et al. randomized 53 individuals with PHPT to observation versus 
parathyroidectomy and were followed up for up to 2 years. Five domains of the SF-36 
(social functioning, physical functioning, emotional role functioning, vitality and general 
health perception) significantly worsened during the 2-year follow-up without surgery. 
Following parathyroidectomy, only modest, but significant, benefits in social functioning 
and emotional role functioning were observed, with a significant decline in physical 
functioning. Using the Symptom CheckList-90-Revised scale (SCL-90-R), individuals in the 
surgical group demonstrated less anxiety and phobia than individuals who were followed 
without surgery. No significant differences were noted in the other domains and no 
significant worsening was noted in the individuals who were followed without surgery. 
Ambrogini et al.130 randomized 50 individuals with PHPT who were followed for up to 1 
year. At 12 months, the surgical group had significantly improved scores for bodily pain, 
general health perception, vitality and mental health compared with medically managed 
controls, although the absolute differences were modest. No differences were noted in the 
remaining SF-36 or SCL-90-R domains. Bollerslev et al.131 randomized 191 subjects with 
PHPT who were followed for up to 2 years. They used the SF-36 questionnaire and the 
modified Comprehensive Psychopathological Rating Scale (CPRS), using normative 
Swedish data as a comparison. At baseline, individuals with PHPT had lower SF-36 scores 
for vitality, social functioning, emotional role functioning, mental health and the mental 
health component summary than normative controls, as well as a lower CPRS score. A small 
but significant decrease in physical functioning and the physical component summary score 
was observed over 2 years in the observation group, whereas there were no changes noted in 
the surgical group. For the mental health domains, the surgical group had significantly 
increased values for emotional role functioning and mental health at 1 year compared with 
baseline, but not at 2 years. At 2 years, the observation group had increased values for 
mental health from baseline. Using the CPRS questionnaire, both the observation and the 
surgical groups had significantly more symptoms than controls over the 2 years without 
significant change over time. There was a trend towards a better outcome in the surgical 
group at 1 year (P = 0.08) but not at 2 years.
Perrier et al.166 randomized 18 subjects with PHPT to parathyroidectomy or observation and 
followed subjects for up to 6 months in a pilot study of cognition in addition to sleep and 
brain function using functional MRI. No between-group differences in cognition, daytime 
sleepiness or voxel counts by functional MRI were found at 6 months. Total sleep time and 
left precentral gyrus activity were found to be inversely correlated with PTH levels.
Rolighed and colleagues167 recently reported the results of a randomized, placebo-controlled 
study, which investigated whether vitamin D supplementation improved QOL in PHPT. 
Subjects given 2,800 IU of cholecalciferol for 26 weeks before and 26 weeks following 
parahyroidectomy demonstrated significant improvements in 25-hydroxyvitamin D levels. 
However, QOL and muscle strength were not improved with cholecalciferol alone, but QOL 
significantly improved following parathyroidectomy independent of the 25-hydroxyvitamin 
D level. Aberg et al.152 also showed that, although QOL improved following 
parathyroidectomy, no additive effect of vitamin D supplementation was evident at doses of 
1,600 IU daily.
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Outlook
PHPT now often presents without overt target organ involvement. Asymptomatic PHPT 
becomes more evident as countries adopt biochemical screening methods. Revised 
guidelines have helped to identify who among these individuals are recommended to 
undergo parathyroidectomy. However, high-resolution imaging of the skeleton and the 
kidneys have called attention to the fact that the absence of overt symptomatology does not 
rule out involvement. Patients with asymptomatic PHPT need renal and skeletal testing 
before clinical decisions can be made. With a more rigorous evaluative approach, it is likely 
that a greater proportion of patients will meet one or more guidelines for parathyroid 
surgery.
This Primer has highlighted several outstanding research issues that remain to be explored in 
PHPT. Our understanding of normocalcaemic PHPT with regard to diagnosis, natural 
history, epidemiology, pathophysiology and target organ involvement all remain key 
questions to be addressed. The optimal steady-state value of 25-hydroxyvitamin D and 
means by which vitamin D should be replaced in individuals with PHPT who are deficient in 
vitamin D need to be elucidated. A particularly vexing issue relates to neurocognitive 
features that often accompany patients with PHPT. Despite several attempts to provide 
conclusive data on the putative association between neurocognitive function and PHPT as 
well as possible changes after successful parathyroidectomy, we still lack clear evidence in 
support of this idea. Microstructural analyses of bone using noninvasive high-resolution 
imaging technology have given new insights into multiskeletal compartment involvement in 
PHPT, involving both cortical and trabecular bone. More information is needed to determine 
how these findings relate to bone strength and fracture risk and the extent to which 
improvement might follow after successful parathyroid surgery. Although the latest 
guidelines121 recommend a more vigorous approach to biochemical stone risk factor 
analysis in individuals with PHPT who have hypercalciuria, the predictive value and 
reversibility of stone risk after parathyroidectomy are not yet known.
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Box 1
Parameters for the evaluation of patients with PHPT
Laboratory tests
• General markers: biochemical screening panel including measuring the levels 
of creatinine and blood urea nitrogen
• Mineral homeostasis: serum calcium (corrected for albumin) or ionized, PTH 
(second-generation or third-generation assay), phosphate and 25-
hydroxyvitamin D levels
• Urine (24-hour): calcium and creatinine levels. If the urine calcium level is 
>400 mg per day, a stone risk analysis profile (including urinary phosphate, 
oxalate, sodium, uric acid, sulfate and citrate levels) should be performed
• Bone resorption marker: serum C-telopeptide crosslinked type I collagen or 
urine N-telopeptide of type I collagen levels*
• Bone formation marker: serum bone-specific alkaline phosphatase, 
procollagen type I N-propeptide or osteocalcin levels*
• If clinically indicated: genetic testing
Imaging
• Bone mineral density analysis by DXA of the lumbar spine, hip (total and 
femoral neck) and distal one-third of the radius
• Vertebral fracture evaluation by X-ray or vertebral fracture assessment by 
DXA
• Abdominal imaging for kidney stones or nephrocalcinosis (ultrasonography, 
CT or abdominal X-ray)
• Optional, if available: high-resolution peripheral quantitative CT or trabecular 
bone score evaluation using DXA
DXA, dual-energy X-ray absorptiometry. *Many clinicians find bone formation and bone 
resorption markers to be helpful as they indicate the level of bone turnover. All the 
available bone turnover markers are listed, but if the clinician elects to obtain this 
information, only a single bone formation and a single bone resorption marker would be 
necessary.
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Box 2
Causes of secondary hyperparathyroidism
Secondary hyperparathyroidism includes conditions in which the parathyroid hormone 
(PTH) level is increased because of a stimulus that expectedly would increase the levels 
of PTH.
Decreased intestinal calcium absorption
• Vitamin D deficiency: serum 25-hydroxyvitamin D levels of <20 ng per ml
• Bariatric surgery
• Malabsorption syndromes
• Decreased calcium intake
Renal insufficiency (eGFR of <60 ml per minute)
• Hypercalciuria
• Loop diuretics
Hungry bone syndrome
• After successful parathyroid surgery for symptomatic primary 
hyperparathyroidism with overt skeletal involvement (osteitis fibrosa cystica), 
a period of time can follow when PTH levels are increased. This is a response 
to the body’s need to accrue skeletal calcium and, in this setting, endogenous 
PTH is overproduced temporarily to meet this need
Pseudohypoparathyroidism
• This genetic disease of PTH resistance is associated with hypocalcaemia and 
increased levels of PTH
Drugs
• Short-term lithium use
• Hydrochlorothiazide
• Anticonvulsants, occasionally, if associated with vitamin D deficiency
• Antiresorptive agents (for example, bisphosphonates and denosumab)
eGFR, estimated glomerular filration rate.
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Box 3
Guidelines for parathyroidectomy
Parathyroidectomy is recommended for symptomatic and asymptomatic patients who 
meet any of the following criteria168:
• Age <50 years
• Serum calcium concentration of ≥1 mg per dl above the upper normal limit
• T-score at or below −2.5 at the lumbar spine, femoral neck, total hip or distal 
one-third of the radius, or the presence of vertebral fracture by X-ray or 
vertebral fracture assessment
• Creatinine clearance of <60 ml per minute, increased risk of kidney stones by 
biochemical stone risk analysis, and kidney stones or nephrocalcinosis by 
abdominal imaging
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Figure 1. Incidence of PHPT
The incidence of primary hyperparathyroidism (PHPT) in women (part a) and men (part b) 
as determined from a large epidemiological database from the United States. Over a 15-year 
period, the incidence tripled even in the setting of routine use of biochemical screening 
tests5. Republished with permission of Endocrine Society, from Incidence and prevalence of 
primary hyperparathyroidism in a racially mixed population, Yeh, M. W. et al., 98, 3, 1122–
1129, 2013; permission conveyed through Copyright Clearance Center, Inc.
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Figure 2. Control of parathyroid hormone synthesis and secretion
In humans, the parathyroid hormone gene (PTH) is located on chromosome 11. The 
formation of mature PTH requires cleavage of the pre-sequences and pro-sequences (25 and 
6 amino acid residues, respectively); the mature PTH peptide (84 amino acids) is packaged 
into secretory vesicles in the parathyroid chief cells. PTH can either be secreted by 
exocytosis, degraded within the secretory vesicles (producing fragments that are released in 
the circulation) or sequestered in a stored pool169. The principal regulators of PTH secretion 
are extracellular ionized calcium (Ca2+) and 1,25-dihydroxyvitamin D (1,25(OH)2D). Other 
potentially important regulators include serum phosphate and fibroblast growth factor 23 
(FGF23). A rise in extracellular ionized calcium levels activates the calcium-sensing 
receptor (CASR), which suppresses PTH expression. In addition, PTH expression is 
suppressed by 1,25(OH)2D and FGF23. FGFR1, fibroblast growth factor receptor 1; VDR, 
vitamin D receptor.
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Figure 3. Relationship between calcium and parathyroid hormone levels in normal conditions 
and in PHPT
In normal conditions, the level of parathyroid hormone (PTH) secretion depends on the level 
of calcium, with a high level of PTH secreted when serum calcium is at the lower limit of 
the normal range and a low level when serum calcium is at the upper limit of the normal 
range. The range of normal serum calcium levels is indicated by the shaded area. The 
calcium set point corresponds to the concentration of calcium, which reduces PTH secretion 
by 50%. In primary hyperparathyroidism (PHPT), the parathyroid adenoma is relatively 
insensitive to the feedback suppression by calcium, and the curve is shifted to the right with 
an increase in the set point for serum calcium. As a consequence, PHPT is often associated 
with hypercalcaemia.
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Figure 4. Oncogenes and tumour-suppressor genes in parathyroid tumours
a | Proto-oncogenes have a physiological role in the control of cell proliferation, 
differentiation and cell death. The conversion of proto-oncogenes to oncogenes (due to 
chromosome inversion, translocation or point mutation) causes an increased expression of its 
encoded protein or the synthesis of a new protein with increased function. Most oncogenes 
are dominant mutations; a single copy of the gene is sufficient to promote tumorigenesis. 
The conversion of a proto-oncogene mainly occurs in somatic cells. Its presence in a 
germline cell does not necessarily result in neoplastic transformation, but can increase the 
risk of it in the offspring. b | Tumour-suppressor genes encode proteins that normally inhibit 
cell proliferation and, once mutated, contribute to tumour development through their 
functional inactivation. Loss-of-function mutations in tumour-suppressor genes act 
recessively; one copy of the gene suffices to control cell proliferation. Inactivation of a 
tumour-suppressor gene is usually caused by point mutations or deletions, which may either 
be inherited in all parathyroid cells or occur somatically in a single parathyroid cell (first 
hit). An acquired somatic deletion or mutation of the other copy of the gene (second hit) will 
lead to loss of function of the related gene product.
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Figure 5. Parathyroid tumorigenesis
(1) Cyclin D1 (encoded by CCND1), a regulatory subunit of cyclin-dependent kinase 4 
(CDK4) and CDK6 required for progression through the G1 phase of the cell cycle, is 
frequently (20–40%) overexpressed in parathyroid adenomas. In a subset of these adenomas, 
a pericentromeric inversion of chromosome 11 places the parathyroid hormone gene (PTH) 
promoter sequences on 11p15 immediately upstream of CCND1. This rearrangement results 
in the upregulated expression of cyclin D1 upon activation of CDKs. (2) Loss-of-function 
mutations of MEN1 (which encodes menin) represent the main cause of multiple endocrine 
neoplasia type 1 (MEN1) syndrome (in up to 80% of cases), especially in the familial 
setting, but are also found in a subset of familial isolated hyperparathyroidism (FIHP) and in 
12–35% of sporadic parathyroid adenomas. MEN1 functions as a classic tumour-suppressor 
gene and is frequently associated with somatic loss of heterozygosity. Menin is a component 
of the histone methyltransferase complex, including the histone-lysine N-methyltransferases 
MLL1 (encoded by KMT2A) and MLL2 (encoded by KMT2D), required for histone H3 
lysine 4 trimethylation (H3K4Me) of the target genes. In physiological conditions, activation 
of this complex leads to the basal transcription of CDKN1B, encoding the CDK inhibitor 
p27 (KIP1), which stops progression of the cell cycle by inhibiting CDK complexes acting 
at multiple phases of the cell cycle, especially at G1-S and S-G2 checkpoints. MEN1 
inactivation results in a reduction of nuclear expression levels of p27 (KIP1) and the loss of 
negative control of cell cycle progression. (3) CDKN1B germline mutations are the 
molecular cause of the MEN4 syndrome. CDKN1B is an atypical tumour-suppressor gene 
because biallelic inactivation is an uncommon event, suggesting that only a single 
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inactivated copy of the gene is sufficient to lead to a diseased state (haploinsufficiency). (4) 
Somatic and germline inactivating CDC73 (which encodes parafibromin) mutations have 
been frequently identified in patients with parathyroid carcinoma. Germline CDC73 
mutations are also responsible for hyperparathyroidism-jaw tumour syndrome (HPT-JT). 
Parafibromin binds to DNA and leads to repression of cyclin D1 and inhibition of 
proliferation. In case of CDC73 inactivation, parafibromin seems to associate with β-
catenin, a central mediator of WNT signalling, and activates target genes (for example, 
MYC and CCDN1) through H3K4Me.
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Figure 6. Overt bone disease in PHPT
Osteolytic lesion due to a brow n tumour of the jaw from an individual with severe primary 
hyperparathyroidism (PHPT; arrow; part a and part b). In addition, note the increased uptake 
of 99m-technetium-methyl diphosphonate on the bone scan (arrow; part c and part d).
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Figure 7. Preoperation location of a parathyroid adenoma
Parathyroid adenoma in the left lower pole of the parathyroid gland is seen by 99m-
technetium-sestamibi scanning (arrow). The faint outlines of the thyroid gland are also seen.
Bilezikian et al. Page 36
Nat Rev Dis Primers. Author manuscript; available in PMC 2017 April 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Bilezikian et al. Page 37
Table 1
Gene abnormalities associated with syndromic and non-syndromic forms of PHPT
Disorder OMIM entry Gene Chromosomal locus Pattern of inheritance
Syndromic forms of PHPT
MEN1 131100 MEN1 11q13.1 Autosomal dominant
MEN2A 171400 RET 10q11.21 Autosomal dominant
MEN4 610755 CDKN1B 12p13.1 Autosomal dominant
Hereditary hyperparathyroidism-jaw tumour 145001 CDC73 (also 
known as 
HRPT2)
1q31.2 Autosomal dominant
Non-syndromic forms of PHPT
Familial isolated hyperparathyroidism 145000 MEN1, 
CDC73 and 
CASR, among 
others*
11q13.1,1q31.2 and 3q13.3–q21.1 Autosomal dominant
FHH type 1 145980 CASR 3q13.3–q21.1 Autosomal dominant
FHH type 2 145981 GNA11 19p13.3 Autosomal dominant
FHH type 3 600740 AP2S1 19q13.32 Autosomal dominant
Neonatal severe hyperparathyroidism 239200 CASR 3q13.3–q21.1 Autosomal recessive
FHH, familial hypocalciuric hypercalcaemia; MEN, multiple endocrine neoplasia; OMIM, Online Mendelian Inheritance in Man; PHPT, primary 
hyperparathyroidism. *Not yet identified.
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Table 2
Assessment of quality of life in PHPT
Study Quality of life and neurocognition Psychological symptoms
Prospective study
Walker et al.163 Worse scores for immediate and delayed recall of contextually 
related material (Wechsler Memory Scale Logical Memory Test) 
in patients with PHPT compared with controls, both of which 
improved 6 months after parathyroidectomy; non-verbal 
abstraction (Booklet Category Test) was worse compared with 
controls and improved after parathyroidectomy
More symptoms of depression (Beck Depression 
Index), and state and trait anxiety (State-Trait 
Anxiety Inventory) in patients with PHPT compared 
with controls; significant improvements in 
depression and trait anxiety 6 months after 
parathyroidectomy
Randomized controlled trials
Rao et al.129 Modest but significant improvements in social functioning and 
emotional role functioning in individuals 1 year after 
parathyroidectomy compared with medical management (SF-36)
Modest but significant improvements in anxiety and 
phobia in individuals 1 year after parathyroidectomy 
compared with medical management (SCL-90-R)
Ambrogini et al.130 Modest but significant beneficial effects on bodily pain, general 
health perception, vitality and mental health in individuals 1 year 
after parathyroidectomy compared with medical management 
(SF-36)
No between-group differences 1 year after 
parathyroidectomy (SCL-90-R)
Bollerslev et al.131 Modest but significant improvements in mental health and the 
mental component summary scores 1 year, but not two years, 
after parathyroidectomy compared with medical management 
(SF-36)
No between-group differences (Comprehensive 
Psychopathological Rating Scale)
PHPT, primary hyperparathyroidism; SCL-90-R, Symptom Checklist-90-Revised scale; SF-36, 36-Item Short-Form Health Survey.
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